AbVitro launches PairMe Grant Challenge to provide access to AbPair technology

AbVitro Inc., an immuno-oncology discovery company, today announced access to its AbPairTM technology by launching the "PairMe Grant Challenge."

AbPair™ allows for the simultaneous discovery and proper native pairings of both B cell immunoglobulin and T cell receptor sequences from millions of single cells simultaneously using our proprietary Next-Generation Immune Sequencing Technology.

The unique aspects of this cutting-edge technology allow for:

  • Unparalleled throughput of millions of single cells per experiment.
  • Full-length variable sequences, with isotype identification.
  • All cell types: memory, naive, plasmablasts, Th, Treg.
  • B and T cells simultaneously in a single experiment.
  • Sequencing of Tumor Infiltrating Lymphocytes (TILs) directly from a tumor sample without the need for isolation or in vitro activation.
  • Simultaneous Identification of associated genes or protein markers (CD4, CD8, PD1, etc.).

The "PairMe Grant Challenge" allows any qualified Academic Institution to submit a short scientific proposal, from which the company will select one or more winners every three months. The winners will receive one AbPair™ sequencing run of up to one million cells, with corresponding data analysis including all B and/or T cell paired sequences discovered--all free of charge.

"A fundamental problem in immunology is the recovery of B cell and T cell receptors in their native pairing configuration at the throughput necessary to truly understand the immune responses of patients or animals. The technology we have developed at AbVitro is unique when compared to other approaches in that we can determine the proper full length pairing of millions of B and T-cells simultaneously, and we wanted to provide access for the scientific community to this powerful tool," stated Francois Vigneault, Ph.D., AbVitro's co-founder and chief scientific officer.

"We developed AbPairTM as part of our own internal discovery efforts in immuno-oncology, but quickly realized that the technology was so disruptive that we wanted to find a way to help the academic scientific community benefit from its potential. We are really excited to share this opportunity and contribute to the advancement of basic immunology research," stated Jeffrey M. Ostrove, Ph.D., chief executive officer of AbVitro.

The first round of applications and proposals for the PairMe Grant Challenge are due October 15th. The winners will be announced October 31st.

Source:

AbVitro Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy